Investor relations

Imprint Privacy policy Code of Conduct

Voyager transaction

Press releases

Events & conferences

Scientific publications

Latest press releases

View All

June 18, 2026

VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026

BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the Company’s two viable and clearly differentiated product platform technologies.

June 10, 2026

VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

Upcoming events

View All

Jun 11, 2026

June 11, 2026

VERAXA's 1st Day of Trading

View event

Jun 11, 2026

June 11, 2026

VERAXA's 1st Day of Trading

View event

Latest scientific publications

View All

April 20, 2026

An avidity-driven, dual-targeting ADC with superior tumor selectivity for the treatment of solid tumors

Steffen Runz, Paul Sauter, Sebastian Latwiel, Jennifer Volkind, Jawad Iqbal, Wilma Neumann, Helga Groetsch, Dina Osmanovic, Abdul-Habib Maag, Anja Schreiber, Christine Köhler, Tatjana Schneidt, Anna Pryszlak, Christoph Erkel, Richard J. Austin

View post

April 20, 2026

A conditionally-active, dual-targeting BiTAC-TCE with superior tumor selectivity for the treatment of solid tumors

Steffen Dickopf, Jorge A. Lerma Romero, Jessica Seib, Laura Perucho-Aznar, Steffen Runz, Anja Schreiber, Abdul-Habib Maag, Anna Pryszlak, Martha Gschwandtner, Christoph Erkel, Richard J. Austin

View post

October 31, 2023

Remodeling the cellular stress response for enhanced genetic code expansion in mammalian cells

Mikhail E. Sushkin, Christine Koehler & Edward A. Lemke

View post